Prothena experienced severe financial deterioration with net losses doubling to $244M while burning through $164M in cash, reducing stockholders' equity by 42% and total assets by 40%.
The company is experiencing a significant cash burn crisis that threatens its financial sustainability, with stockholders' equity declining from $487M to $281M in just one year. While R&D expenses decreased 39%, this wasn't enough to offset the massive increase in net losses, suggesting either substantial one-time charges or operational inefficiencies that require immediate investor attention.
Despite reducing R&D spending by $88M (-39%), Prothena's net losses nearly doubled from $122M to $244M, indicating significant non-operational charges or expenses. The company burned through $164M in cash while total assets declined 40% and stockholders' equity fell 42%, creating a concerning financial trajectory. The modest revenue increase to $814K provides little relief against the massive loss expansion, signaling potential liquidity concerns if the current burn rate continues.
Strong top-line growth of 297.1% — accelerating demand or successful expansion into new markets.
Net income declined 99.6% — review whether driven by operations, interest costs, or non-recurring items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 40.3% — asset sales, write-downs, or balance sheet optimization underway.
R&D spending cut 39.4% — could signal cost discipline or concerning reduction in innovation investment.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current assets declined 35.1% — monitor working capital adequacy and short-term liquidity.
Cash declined 34.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Liabilities reduced 23% — deleveraging improves balance sheet strength and financial flexibility.
Current liabilities reduced — improved short-term financial position and working capital health.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →